Safety and Tolerability Profile

Treatment-emergent adverse events (TEAEs) ≥1% for GRALISE patients and more frequent than placebo1

The majority of TEAEs reported with GRALISE were mild to moderate.1

The most common TEAEs with GRALISE were dizziness (11%) and somnolence (5%).1